Direct Cardiac Reprogramming with Engineered miRNA Scaffolds.

Direct Cardiac Reprogramming with Engineered miRNA Scaffolds. Curr Pharm Des. 2020 Mar 27;: Authors: Muniyandi P, Maekawa T, Hanajiri T, Palaninathan V Abstract Ischemic heart disease is a predominant cause of death worldwide. The loss or death of cardiomyocytes due to restricted blood flow often results in a cardiac injury. These injured cardiomyocytes are replaced by myofibroblasts that preserve structural integrity. However, the depleted cardiomyocytes lead to cardiac dysfunction such as pathological cardiac dilation, reduced cardiac contraction and fibrosis. Repair and regeneration of myocardium are the best possible therapy for the end-stage heart failure patients because the current therapies that can help restore the lost cardiomyocytes are limited to heart transplantation only. Emerging interests to directly reprogram a mammalian heart with minimal regenerative capacity holds a promising future in the field of cardiovascular regenerative medicine. Since heart muscles have no alternative replacements like heart valves or blood vessels, repair and regeneration become two crucial 'R's in the field of cardiovascular regenerative medicine. Despite various strategies to reprogram with diverse factors like small molecules, genetic and epigenetic regulators for cardiac regeneration there are limitations such as low efficacy, immunogenic problems, an unsafe delivery system that pose a daunting challenge in human trial translations. He...
Source: Current Pharmaceutical Design - Category: Drugs & Pharmacology Authors: Tags: Curr Pharm Des Source Type: research